medRxiv
October 15, 2026
Chlöé Müh, Pauline Favre, Isabel Karen Lütkenherm et al.
preprint
Abstract Negative emotional bias, including reduced processing of positive information and negative interpretation of ambiguous stimuli, is a core feature of depression. Esketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist with rapid antidepressant effects in treatment-resistant depression (TRD), reduces depressive symptoms, but its effects on distinct components of emotional...
Epigenetics
October 15, 2026
Arghavan Nepton, Sonya C. Faber, Zachary A. Kaminsky et al.
Ketamine produces rapid antidepressant effects, but the molecular processes associated with their persistence remain poorly defined in humans. We examined longitudinal DNA methylation changes in 10 adults with major depressive disorder undergoing ketamine-assisted psychotherapy using two pre-treatment assessments (T1, T2) and one post-treatment assessment (T3). Participants received three...
Frontiers in Psychology
October 14, 2026
Georgi Panov, Presiyana Panova
Both quantum mechanics and cognitive neuroscience challenge the classical view of a passively perceived reality. Instead, they suggest that reality arises through a process of selection and stabilization from a field of possibilities. This article proposes that this “reality stabilization” framework can unify our understanding of psychosis and post-psychotic depression—two conditions that are...
Preprints.org
October 14, 2026
Domenico de Berardis, Tommaso Barlattani, Alessandro Carano et al.
preprint
Intranasal esketamine has been available for treatment-resistant depression (TRD) since 2019, but the trials that led to its approval answer only some of the questions prescribers face. About 97% of trial participants had failed only one or two antidepressant classes, and patients with bipolar disorder, psychosis, obsessive–compulsive disorder, four personality disorders, moderate-to-severe...
Current Neuropharmacology
October 14, 2026
Mareli Vázquez-Barreto, Mariana Ugarte-Rocha, Abraham Flores Vargas et al.
Mental disorders are among the leading causes of non-fatal health loss worldwide and are associated with significant individual, social, and economic burdens. On the other hand, neuropathic pain affects approximately 7-8% of the world's adult population and is a leading reason for medical consultations. A bidirectional relationship between depression and pain has been widely documented....
Research Portal
October 13, 2026
Tamsin Ford, Rachel Childs, Rachel Hayes et al.
Adolescents and carers using mindfulness Therapy To END depression (ATTEND): Study Protocol for a parallel randomized controlled superiority trial of Mindfulness for Adolescents and Carers (MAC) for depression among young people aged 15 to 18 years old in the UK with an embedded economic evaluation.
Australasian Psychiatry
October 13, 2026
Adam Bayes, Colleen Loo
ObjectiveThe ideas presented in this paper are based on a presentation at a festschrift event marking the retirement of Professor Gordon Parker from UNSW, Sydney. Drawing on Gordon's depressive subtyping approach and his critiques of a unitary view of major depressive disorder and treatment-resistant depression (TRD), we aim to (i) explore differing models of ketamine for TRD - biomedical...
Journal of Affective Disorders
October 12, 2026
Reinhard Janssen-Aguilar, Jithin Joseph, Huda Al-Shamali et al.
Treatment-resistant depression (TRD) affects 30-60% of individuals with major depressive disorder and carries substantial morbidity and healthcare costs. Intravenous (IV) ketamine (KET) is a rapid-acting antidepressant, but benefits are often transient, prompting augmentation to sustain efficacy or improve tolerability. We conducted a systematic review and meta-analysis of randomized controlled...
Asian Journal of Psychiatry
October 12, 2026
Gia Han Le, Sabrina Wong, Simryn Selby et al.
Ketamine is a rapid-acting antidepressant with demonstrated efficacy in major depressive disorder and treatment-resistant depression, yet the mechanisms by which its molecular actions translate into sustained clinical improvement remain incompletely understood. Prevailing models have emphasized N-methyl-D-aspartate receptor antagonism and downstream glutamatergic signaling; however, convergent...
Journal of Molecular Neuroscience
October 12, 2026
Meitar Grad, Hadas Volkov, Noam Shomron
Abstract Major depressive disorder (MDD) is a prevalent psychiatric disorder, and is a leading cause of disability worldwide. Current treatments for MDD entail many side effects, and include a lag until the onset of therapeutic effects. The current hypotheses as for the etiology of MDD revolve around the monoamine hypothesis and the plasticity and neurodegeneration hypothesis. According to the...